Acquisition strengthens Aspire Pharma’s strategic portfolio
Aspire Pharma, a rapidly growing UK-based specialty generics business, has announced the acquisition of Charlwood Pharma, a privately-owned company specializing in the research and development of niche generic medicines.
The acquisition marks the culmination of a successful multi-year collaboration between the two organizations.
Charlwood brings to Aspire a robust pipeline of products spanning mental health, ear, nose and throat (ENT), cardiovascular and respiratory therapy areas - complementing Aspire’s existing portfolio and growth strategy.
Richard Condon, Aspire Pharma chief executive, said: "This acquisition not only strengthens our existing portfolio, but also stands as a testament to the value of long-term partnerships with Aspire, which deliver meaningful innovations that enhance patient care.
"Under the terms of this agreement, Aspire will assume full ownership of all intellectual property, which reinforces our ambitions for international expansion.
"This acquisition further demonstrates Aspire’s commitment to delivering quality, affordable medicines that support the highest levels of patient care, while offering true value to healthcare systems throughout the world."
